Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer

NCT00063999 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.

NCT NCT00063999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00063999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer
Lead sponsor
GOG Foundation
Phase
Phase 3
Overall status
Completed
Start date
August 25, 2003
Completion date
January 5, 2021
Enrollment
1,381 (actual)
Sites
650

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent uterine corpus carcinoma, stage iiia uterine corpus cancer ajcc v7, stage iiib uterine corpus cancer ajcc v7, stage iiic uterine corpus cancer ajcc v7, stage iva uterine corpus cancer ajcc v7, stage ivb uterine corpus cancer ajcc v7